Update on the role of ceftazidime-avibactam in the management of carbapenemase-producing Enterobacterales
Update on the role of ceftazidime-avibactam in the management of carbapenemase-producing Enterobacterales
复制标题
DOI：
10.2217/fmb-2020-0012
复制
发表时间：
2020-05-01
影响因子：
3.1
通讯作者：
Garau, Javier
中科院分区：
文献类型：
--
作者：
Dietl, Beatriz;Martinez, Laura M.;Garau, Javier
Ceftazidime-avibactam是一种已知头孢菌素和非β -内酰胺/ β -内酰胺酶抑制剂的新型组合，已被批准用于治疗复杂的腹腔和尿路感染，医院获得性肺炎以及革兰氏阴性感染，治疗方案有限。自获批以来，它已被用于碳青霉烯耐药细菌感染的患者，在许多情况下作为适应症外适应症或补救性治疗，具有良好的临床和微生物治愈率。在对这种新组合的治疗过程中出现的耐药性已经被描述，这是一个值得关注的问题。在多药耐药时代，合理使用这些新的治疗方案至关重要。本文综述了头孢他啶-阿维巴坦治疗产碳青霉烯酶肠杆菌的临床经验。
Ceftazidime-avibactam is a novel combination of a known cephalosporin and a non-beta -lactam/beta -lactamase inhibitor that has been approved for the treatment of complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia as well as Gram-negative infections with limited treatment options in Europe. Since its approval, it has been used in patients with infections due to carbapenem-resistant bacteria, in many occasions as off-label indication or salvage therapy, with promising clinical and microbiological cure rates. Emergence of resistance during therapy to this new combination has already been described, which is a matter of concern. A rational use of these new therapeutic options is critical in the multidrug resistance era. The current review focuses on the clinical experience in real life of ceftazidime-avibactam use in the treatment of carbapenemase-producing Enterobacterales.